An abstract entitled “Sn-117m for metastatic bone cancer treatment-modernizing Sn-117m-DTPA for regulatory approval” was accepted for oral presentation by Serene CEO, Gilbert Gonzales, in Saskatoon, Saskatchewan July 23-27, 2023. Three additional abstracts will be presented by Serene COO, Nigel Stevenson. They are entitled “Intra-articular treatment of naturally occurring canine ebow arthritis using homogeneous tin-117m colloid”, “Sn-117m in radiosynoviorthesis for canine osteoarthritis: learnings from 2 years of commercialization”, and “Precision radionuclide therapy for treating veterinary cancerous tumors and osteoarthritis”.